TransMedics director granted 2,922 RSUs
Basile Edward M reported acquisition or exercise transactions in this Form 4 filing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Basile Edward M reported acquisition or exercise transactions in this Form 4 filing.
TransMedics Group, Inc. director Edward M. Basile received a grant of 2,922 shares of common stock in the form of restricted stock units. The award was made at no cash cost per share and is a form of equity compensation. Following this grant, Basile directly holds 5,788 shares of the company’s common stock, showing his stake has increased through stock-based awards rather than open-market purchases or sales.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 2,922 | $0.00 | $0.00 |
Footnotes (1)
- F1. Consists of 2,922 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.
Key Figures
Key Terms
restricted stock units financial
RSUs financial
contingent right financial
Form 4 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did TransMedics (TMDX) report for Edward M. Basile?
Was the recent TransMedics (TMDX) insider transaction a purchase or a grant?
What are the terms of the 2,922 RSUs granted by TransMedics (TMDX)?
AI-generated analysis. How Rhea-AI works. Not financial advice.